Celgene backing Soon-Shiong's cancer biotech IPO, now dubbed NantKwest

Now that billionaire entrepreneur Patrick Soon-Shiong has taken control of tiny ConkWest and steered it toward a $173 million IPO, he's adding a makeover to the name that will fit more easily under the fast-growing NantWorks umbrella he's created. In an amended IPO filing ConkWest is now named NantKwest, which will look to trade under the "NK" symbol on Nasdaq. And Soon-Shiong is bringing some close associates in on the deal, with Celgene (which acquired Abraxis from Soon-Shiong for $3 billion) agreeing to buy $17 million worth of shares on the debut and funds at Franklin Templeton committing to a $45 million buy. For the record, the little immuno-oncology player had spent about $46 million by the time Soon-Shiong stepped in earlier this year, raised cash for the company and pointed it to the public market in record time. Filing

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.